RecruitingPhase 2 / Phase 3NCT07063745
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Sponsor: Bristol-Myers Squibb
Hershey, PA · +43 more sites